# Centene Corporation – Consensus ‘buy’ rating and 18.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/centene-corporation-consensus-buy-rating-and-18.5-upside-potential/4121134772
- Published: 2023-12-01T11:37:44+00:00
- Author: Charlotte Edwards

**Centene Corporation** with ticker code (CNC) now have 15 analysts in total covering
the stock. The consensus rating is pointing to ‘buy’. The range between the high
target price and low target price is between $110.00 and $72.00 with the average
target price sitting at $83.53. Now with the previous closing price of $70.48 this
is indicating there is a potential upside of 18.5%. The 50 day MA is $70.90 and 
the 200 moving average now moves to $67.62. The company has a market cap of 39.36B.
The current share price for the company is: $73.68 USD

 The potential market cap would be $46,647,772,186 based on the market consensus.

The company has a dividend yield of 1.57%. Other points of data to note are a P/
E ratio of 16.34, revenue per share of $253.50 and a 3.85% return on assets.

Centene Corporation is a healthcare company. The Company provides services to government-
sponsored and commercial healthcare programs, focusing on under-insured and uninsured
individuals. It provides a range of managed healthcare products and services, primarily
through Medicaid, Medicare, and commercial products. Its segments include Medicaid,
Medicare, Commercial and Other. It offers Medicaid and Medicare members (including
Medicare Prescription Drug Plans) as well as individuals and families served by 
the Health Insurance Marketplace and the TRICARE program. It also contracts with
other healthcare and commercial organizations to provide a variety of specialty 
services focused on treating the whole person. Medicaid program provides health 
insurance to low-income families and individuals with disabilities. Medicare is 
a federal health insurance program for people ages 65 and over, which also covers
people under 65 with certain disabilities and people with end-stage renal diseases.

Share on: